MedTrace Logo

Breast Cancer With Over-expression of erbB2-BRAINSTORM

NCT01064349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2018-09-14

No results posted yet for this study

Summary

This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression.

Conditions

Interventions

DRUG

Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer

Trastuzumab or Lapatinib

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-06
Primary Completion
2011-06-03
Completion
2011-06-03

Countries

  • Philippines
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01064349 on ClinicalTrials.gov